Оригинален текст - Английски - ASSESSMENT OF SMALL BOWEL SAFETY OF LUMIRACOXIB 100 MG OD

Of 152 randomized subjects, 139 completed the study with valid VCEs. Compared with placebo, an increased number of subjects on naproxen plus omeprazole had small bowel mucosal breaks , with increased permeability and raised faecal calprotectin . .There was no increase in permeability. As assessed by three different measures, acute small bowel injury on lumiracoxib treatment is less frequent than with naproxen plus omeprazole and similar to placebo.